Nucleic Acids and Precision Therapies for Neuroprotection

1. Auflage 2026
ISBN: 978-1-032-68673-8
Verlag: Taylor & Francis Ltd

Buch, Englisch, 488 Seiten, Format (B × H): 210 mm x 297 mm, Gewicht: 453 g

Reihe: Neuroscience of Neurodegenerative Disease

Neurodegenerative disorders are rising worldwide, yet most approved drugs merely temper symptoms. Nucleic Acids and Precision Therapies for Neuroprotection addresses this therapeutic shortfall directly, tracing how antisense oligonucleotides, RNA interference agents, mRNA platforms, aptamers, and CRISPR-class editors are redefining what “treatable” means for Alzheimer’s, Parkinson’s, ALS, Huntington’s disease, and Multiple Sclerosis.

Rather than cataloguing modalities in isolation, the book lays out an end-to-end translational roadmap from target identification and sequence optimisation to blood–brain barrier traversal, immunogenicity management, scalable manufacturing, and ethical oversight. Delivery science (including viral, nanoparticle, and hybrid vectors), AI-enabled biomarker discovery, adaptive trial architectures, and shifting global regulatory frameworks are viewed as interlocking elements of a single development pathway.

By aligning disparate scientific “dialects” into a shared, practice-oriented language, Nucleic Acids and Precision Therapies for Neuroprotection offers what the field currently lacks: a cohesive guide for moving nucleic acid therapeutics from concept to clinic with precision. Researchers, clinicians, regulators, and industry teams will find pragmatic frameworks, comparative tables, and decision points that shorten the path between mechanistic insight and patient impact without sacrificing rigour or transparency.

Zielgruppe

Academic, Postgraduate, Professional Practice & Development, and Professional Reference

Autoren/Hrsg.

Koduru, Trideva Sastri

Fachgebiete

• Interdisziplinäres Wissenschaften Wissenschaften Interdisziplinär Neurowissenschaften, Kognitionswissenschaft
• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Biotechnologie Medizinische Biotechnologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft

Inhaltsverzeichnis

1. Introduction to Neurodegenerative Disorders

2. Traditional Therapies for Neurodegenerative Diseases

3. Nucleic Acid Therapies for Neurodegenerative Disorders

4. Antisense and RNA-Interference Strategies for Neurodegeneration

5. Aptamer and mRNA Platforms for Receptor Targeting and Protein Replacement

6. Genome Editing and Next-Generation Nucleic-Acid Tools

7. Precision Medicine and Nucleic Acid Therapies for Neurodegenerative Disorders

8. Challenges in the Development and Application of Nucleic Acid Therapies for Neurodegenerative Disorders

9. Approaches for the Delivery of Nucleic Acid Therapies in Managing Neurodegenerative Disorders

10. AI and Nucleic Acid Therapeutics in Neurodegenerative Disease

11. Clinical trials of Nucleic Acid therapies for neurodegenerative disorders

12. Regulatory Considerations for Nucleic Acid Therapies in Neurodegenerative Disorders

13. Future Perspectives and Challenges in Nucleic Acid Therapies for Neurodegenerative Disorders

Über Autor(innen)

Dr. K. Trideva Sastri Koduru is a faculty member in Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, India. His PhD work pioneered the use of intranasal nanostructured lipid carriers for miRNA-based modulation of multiple sclerosis, supported by a Senior Research Fellowship from the ICMR’s Innovation & Translation Research division. He specialises in nano-carrier platforms for nucleic acid delivery, with a focus on neurological and autoimmune disorders, and brings complementary strengths in formulation design, bioanalytical method validation, and pharmacokinetics. Dr Sastri has strong expertise in miRNA-based drug delivery systems. He has made significant contributions to the pharmaceutical and drug delivery community by publishing several peer-reviewed papers in reputable journals, as well as editing and authoring scholarly chapters and volumes with Academic Press, CRC Press, and Springer. Dr. Sastri’s research focuses on nanoscience-aided drug carrier systems and the genetic complexities of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. His forthcoming endeavours centre on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences